Omri Amirav-Drory

Omri Amirav-Drory has extensive experience in various roles within the biotech industry. Starting in 2021, they served as a Board Member for multiple companies, including Nanocarry Therapeutics, Pepper Bio, PANGEA Therapeutics, La Jolla Labs, Mana.bio, Talus Bio, and resistanceBio. In 2022, Omri became a Founder & CEO at Renewal Bio and a Board Observer at Centivax. Their most recent role is as a Board Member for ZipBio, starting in 2023.

Omri Amirav-Drory began their education at Tel Aviv University, where they pursued a Bachelor of Science degree in Biochemistry and Molecular Biology from 2001 to 2003. Omri then continued their academic journey at the same institution to obtain their Doctor of Philosophy (Ph.D.) in Biochemistry, completing their studies from 2003 to 2007. Following this, Omri pursued a postdoctoral position at Stanford University, specializing in Biochemistry and Molecular Biology. Omri completed this postdoctoral fellowship from 2007 to 2011.